PubMed
Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295
Teichman et al., 2006
GH SecretagoguesCompoundableB
CJC-1295
CJC-1295 DAC
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- B
- Experience
- 98
- Activity
- 78
Overall check-ins
Trackers & reports
Overview
About CJC-1295
CJC-1295 is a tetrasubstituted peptide analog of GHRH with a drug affinity complex (DAC) modification — a reactive maleimide group that forms a covalent bond with serum albumin after injection. This dramatically extends its half-life from minutes to 6–8 days, allowing once-weekly dosing with sustained GH and IGF-1 elevation. Available through compounding pharmacies with a prescription.
- Category
- GH Secretagogues
- Regulatory status
- Compoundable
- Also known as
- CJC-1295 DAC
- Self-reports
- 33
Community
What 33 users report
33 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 96% · Mixed 4% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
138
Sleep
138
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Fatigue
2
Headache
2
Water retention
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.1–3 mg
0.1–0.2 mg
24
0.2–0.4 mg
39
0.4–0.6 mg
23
1–2 mg
31
2–3 mg
21
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 48 days · Based on 25 repeat reporters
Research
Cited research (3)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
ClinicalTrials.gov
CJC-1295 growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
Tools
Explore more
Explore
More ways to learn about CJC-1295 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about CJC-1295?
This page summarizes 33 anonymized self-reports from PeptIQ users who track CJC-1295, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for CJC-1295?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for CJC-1295?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is CJC-1295 safe to use?
This wiki does not assess safety or recommend use. CJC-1295 is listed as Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of CJC-1295?
Research, primarily in animal models, suggests CJC-1295 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of CJC-1295?
CJC-1295 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified CJC-1295 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of CJC-1295?
The safety and effectiveness of CJC-1295 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on CJC-1295?
While there are over 200 published studies on CJC-1295, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source